26th week of 2014 patent applcation highlights part 46 |
Patent application number | Title | Published |
20140178302 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors. | 2014-06-26 |
20140178303 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS - Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids). | 2014-06-26 |
20140178304 | RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS - The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of PDE10A in mammals. The compound of the present invention is represented by the formula (I): wherein each symbols are as defined in the specification. | 2014-06-26 |
20140178305 | IDENTIFICATION AND USE OF ANXIOLYTIC COMPOUNDS - The present disclosure provides methods and compositions that can be used to identify anxiolytic compounds, and to treat anxiety in a subject. Methods and compositions for identifying activating stimuli for sensory neurons, for example MrgprB4 | 2014-06-26 |
20140178306 | STEATOHEPATITIS-LIVER CANCER MODEL ANIMAL - Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated. | 2014-06-26 |
20140178307 | METHODS AND ASSAYS FOR TREATING SUBJECTS WITH SHANK3 DELETION, MUTATION OR REDUCED EXPRESSION - Methods and assays are disclosed for treating subjects with 22q13 deletion syndrome or SHANK3 deletion or duplication, mutation or reduced expression, where the methods comprise administering to the subject insulin-like growth factor 1 (IGF-1), IGF-1-derived peptide or analog, growth hormone, an AMPAkine, a compound that directly or indirectly enhances glutamate neurotransmission, including by inhibiting inhibitory (most typically GABA) transmission, or an agent that activates the growth hormone receptor or the insulin-like growth factor 1 (IGF-1) receptor, or a downstream signaling pathway thereof. | 2014-06-26 |
20140178308 | METHOD FOR INCREASING THE INTRAOCULAR PRESSURE IN AN ANIMAL - The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma. | 2014-06-26 |
20140178309 | PROTECTION OF CELLS FROM ALU-RNA-INDUCED DEGENERATION AND INHIBITORS FOR PROTECTING CELLS - A method of protecting a cell includes inhibiting an inflammasome, MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NFκB of the cell. Administering an inhibitor of MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NFκB can protect the cell from Alu-RNA-induced degeneration. Protecting a cell, such as an retinal pigment epithelium (RPE), can be therapeutically useful in the context of age-related macular degeneration and geographic atrophy. | 2014-06-26 |
20140178310 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents - Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods. | 2014-06-26 |
20140178311 | METHOD OF ADDING BOTANICAL AGENTS/DIETARY SUPPLEMENTS TO PHARMACEUTICAL AGENTS IN A PHARMACOTHERAPEUTIC REGIMEN - A method for administering an active pharmaceutical agent (APA) is provided that includes the steps of: a) providing a medicine having a dose of at least one APA and at least one active botanical agent (ABA) or dietary supplement; and b) dosing the APA within the medicine such that within each subsequent dose of the medicine, the amount of the APA decreases and the amount of the ABA increases, or remains the same, or decreases relative to an earlier amount. A trace of the APA may or may not remain in the pill toward the end of medicine application. | 2014-06-26 |
20140178312 | AZEOTROPE-LIKE COMPOSITIONS COMPRISING 1-CHLORO-3,3,3-TRIFLUOROPROPENE - An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C | 2014-06-26 |
20140178313 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ORAL DISEASES - Provided is a novel lactic acid bacterium strain which is capable of suppressing production of volatile sulfur compounds by oral bacteria, has no cariogenicity and no causative role in infective endocarditis, and is safe in an oral cavity, and provided is an agent for preventing, improving and/or treating oral diseases and discomforts by use of the bacterial strain. | 2014-06-26 |
20140178314 | COMPOSITIONS AND/OR ARTICLES WITH IMPROVED SOLUBILITY OF A SOLID ACTIVE - Personal care compositions for use in an absorbent article are disclosed comprising an isosorbide diester having the formula: | 2014-06-26 |
20140178315 | Topical Compositions Comprising Ionic Fluids - The present invention relates to anhydrous or essentially anhydrous compositions intended for topical application on keratinaceous surfaces, wherein the composition includes a) an ionic fluid and b) a thickener. The compositions are advantageous for allowing the ionic fluid to act as the continuous phase of a topical formulation. | 2014-06-26 |
20140178316 | SKIN TREATMENTS CONTAINING PYRROLOQUINOLINE QUINONE (PQQ) ESTERS AND METHODS OF PREPARATION AND USE THEREOF - The present invention relates to cosmetic or dermatological compositions containing PQQ or its esters, methods of treating or promoting skin changes by topical application of these compositions, and methods of synthesis of PQQ esters. The PQQ ester-containing compositions of the present invention are unexpectedly effective in treating skin, particularly with respect to skin tolerance. When included in a topical composition, the PQQ esters of the present invention have an antioxidant effect that is useful in treating a skin change. | 2014-06-26 |
20140178317 | ANHYDROUS ANTISUN CREAM COMPRISING A NON-EMULSIFYING ELASTOMERIC ORGANOPOLYSILOXANE, A MATTING AGENT AND A NON-SILICONE ORGANIC OIL THICKENER - The present invention relates to an anhydrous composition in cream form, characterized in that it comprises, in a cosmetically acceptable support: (a) at least one oily phase; (b) at least one non-emulsifying elastomeric organopolysiloxane; (b) a photoprotective system capable of screening out UV radiation; (c) at least one matting agent; (d) at least one non-silicone organic thickener for the oily phase, chosen from: (1) crystalline polymers, preferably semi-crystalline polymers, (2) fatty acid esters of dextrin, (3) hydrophobic-modified polysaccharides, (4) crystalline olefin copolymers, (5) crystalline polycondensates, (6) polymers of lipophilic polyamide type, (7) lipophilic polyureas and polyurethanes, (8) block polymers, (9) cholesterol-based liquid-crystal agents and mixtures thereof; the said composition not comprising any humectant. | 2014-06-26 |
20140178318 | NOVEL COMPOUNDS - Methods of making polyglycerol based UV-filters, topical compositions comprising such polyglycerol based UV-filters and the use of such novel polyglycerol based UV-filters to enhance the solubility of butyl methoxydibenzoylmethane or bis-ethylhexyloxyphenol methoxyphenyl triazine in cosmetic oils are provided. | 2014-06-26 |
20140178319 | Modulation Of Melanogenesis By Modification Of Tyrosinase By Palmitoylation - Compositions and methods for modulating melanogenesis by modifying tyrosinase palmitoylation are provided. | 2014-06-26 |
20140178320 | WATER-IN-OIL EMULSION COMPRISING PIGMENTS IN THE WATER PHASE - Provided is a composition and especially a cosmetic composition comprising: A) an oily phase and B) an aqueous phase which comprises: a) water, b) a pigment, c) a modified phospholipid, and d) an alkyl substituted diol comprising 5 or more carbons; wherein the composition is in the form of an water-in-oil emulsion, and wherein the pigment essentially remains in the water phase. Also provide is a method of producing the composition which comprises: 1) obtaining a mixture of a modified phospholipid and an alkyl substituted diol comprising 5 or more carbons in the alkyl chain; 2) obtaining a mixture of water and a pigment; 3) combining the mixture of the modified phospholipids and the alkyl substituted diol with the mixture of the pigment and water; 4) obtaining an oil composition; and 5) combining the mixture from 3) with the oil composition of 4) to form an water-in-oil emulsion. | 2014-06-26 |
20140178321 | TEXTILE FRIENDLY NON-AEROSOL ANTIPERSPIRANTS WITH A HYDROXY ACID - The present application relates to cosmetic antiperspirants for nonaerosol use, having a content of at least one hydroxycarboxylic acid of formula (HCS-1) | 2014-06-26 |
20140178322 | BRIGHTENER-CONTAINING HAIR RELAXER - An improved aqueous human hair relaxer composition is disclosed that contains effective amounts of active human hair straightening ingredients and excipients, and having a pH value of about 12 to about 14, whose improvement comprises the incorporation of a dissolved or dispersed discoloration-inhibiting effective amount of alpha-hydroxy-C | 2014-06-26 |
20140178323 | SALINE STYLING MEDIUM - Products that, when used, provide naturally curly hairstyles include, based on their weight, 0.1 to 20 wt % setting polymer(s), and 0.01 to 1 mol/kg sodium chloride, and 0.0025 to 1 mol/kg polyvalent metal cation(s) of formula Me | 2014-06-26 |
20140178324 | Compositions with pH Responsive Copolymer Containing MAEP and/or MAHP and Method for Using Same - Disclosed is a pH responsive polymer made with mono-[2-(methacryloyloxy)ethyl]phthalate and/or mono-[2-(methacryloyloxy)ethyl hexahydro]phthalate. Also disclosed is an aqueous coating composition including at least one latex polymer derived from at least one monomer copolymerized or blended with alkali swellable acrylate copolymer. Also provided is an aqueous coating composition including at least one latex polymer derived from at least one monomer blended with alkali swellable acrylate copolymer, at least one pigment, and water. Also provided is a method of preparing an aqueous coating composition such as a latex paint including the above components. Also provided are methods of preparing mono-[2-(methacryloyloxy)ethyl]phthalate. Also provided are conpositions and methods using the polymer in hydraulic fracturing, personal care and or home and industrial cleaners. | 2014-06-26 |
20140178325 | Anti-Settling and Thickening Compositions and Methods for Using Same - An anti-settling additive, composition containing the anti-settling additive, and methods for use in coating compositions or formulations. A HASE thickener with improved resistance to surfactants and anti-sag properties, compositions containing the thickener and methods for use of the thickener in coating compositions or formulations and the like. The anti-settling additive and the thickener being a polymer synthesized using a specialized associative monomer that contains C1-C4 alkyl, propylene oxide, ethylene oxide and a polymerizable group. | 2014-06-26 |
20140178326 | COMPOSITIONS - The invention relates to the use of compounds that act on N-alpha acyl glutamine amino acylase enzyme expressed by coryneform bacteria to exert a malodour-counteracting effect, in a composition or article of manufacture suitable for reducing, suppressing or eliminating malodour on inanimate surfaces. The compounds, in particular, may be N-acyl glutamine derivatives. | 2014-06-26 |
20140178327 | Antimicrobial Ophthalmic Devices - Antimicrobial ophthalmic devices such as contact lenses, ocular inserts, ocular bandages, and intraocular lenses comprise a hydrogel and an antimicrobially-effective amount of epsilon polylysine non-covalently attached to the hydrogel. | 2014-06-26 |
20140178328 | IMPLANTABLE POLYMER FOR BONE AND VASCULAR LESIONS - A solidifying prepolymeric implant composition comprising a biocompatible prepolymer and an optional filler. One such implant composition is a polyurethane implant composition comprising an isocyanate, such as hydroxymethylenediisocyanate (HMDI) and an alcohol, such as polycaprolactonediol (PCL diol). The compositions of the invention are useful for improving bone structure in patients by applying the solidifying implant composition to bone, reinforcing bone structure, improving load bearing capacity and/or aiding healing of microfractures. | 2014-06-26 |
20140178329 | VARIANTS OF THE TNF SUPERFAMILY AND USES THEREOF - Described are novel variants of APRIL that modulate signaling via receptor-specific agonist activity, and nucleic acids encoding these variant proteins. Further described is the use of these novel proteins in the treatment of APRIL-associated disorders, in particular, pathologies of the immune system and oncological disorders. | 2014-06-26 |
20140178330 | PH20 Polypeptide Variants, Formulations And Uses Thereof - Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof. | 2014-06-26 |
20140178331 | METHOD OF TREATING CEREBRAL HEMORRHAGE AND SUBARACHNOID HEMORRHAGE COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of cerebral hemorrhage and subarachnoid hemorrhage. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, cerebral hemorrhage and subarachnoid hemorrhage. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the cerebral hemorrhage and subarachnoid hemorrhage. | 2014-06-26 |
20140178332 | IL-12/p40 BINDING PROTEINS - The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental. | 2014-06-26 |
20140178333 | HOMOGENOUS PREPARATIONS OF IL-28 AND IL-29 - Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. | 2014-06-26 |
20140178334 | Methods and compositions for liquidation of tumors - This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication. | 2014-06-26 |
20140178335 | USE OF IL-12 TO GENERATE ENDOGENOUS ERYTHROPOIETIN - The present invention relates to the use of exogenous interleukin-12 (IL-12) for increasing endogenous production of erythropoietin. | 2014-06-26 |
20140178336 | ANTIVIRAL COMPOUNDS - The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2014-06-26 |
20140178337 | HEPATITIS B ANTIVIRAL AGENTS - The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention. | 2014-06-26 |
20140178338 | 4'-FLUORO NUCLOSIDES FOR THE TREATMENT OF HCV - Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: | 2014-06-26 |
20140178339 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 FOR TREATMENT OF CANCER - Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk signaling pathway, and/or expresses an activated or oncogenic BRAF or RAS. | 2014-06-26 |
20140178340 | CANCER COMBINATION THERAPY AND RECOMBINANT VECTORS - This disclosure relates to a combination therapy of chemotherapeutics and/or radiosensitizing agents with a replication competent viral vectors for treating cell proliferative disorders and chemotherapeutic treatments. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics. | 2014-06-26 |
20140178341 | INDIVIDUALIZED BACTERIAL TREATMENT OF PANCREATIC CANCER - An individualized bacterial treatment of cancer is provided. The treatment includes a strain of bacteria modified by in-vivo passage through tumor grafts in experimental animals, where the modified strain exhibits enhanced cancer cell-targeting of a specific malignancy arising in a unique individual to the corresponding parent strain of bacteria. The treatment uses this modified strain for the treatment human solid-tumor malignancies by inoculating an individual with a quantity of the strain; and repeating inoculations at periodic intervals where repeated inoculations tend to progressively eliminate the solid tumor malignancy in the individual. | 2014-06-26 |
20140178342 | Method For Treating Infectious Skin Diseases Using Live Penicillium Notatum Fungus - The invention relates to a method for treating skin diseases using live “ | 2014-06-26 |
20140178343 | SUPPORTS AND METHODS FOR PROMOTING INTEGRATION OF CARTILAGE TISSUE EXPLANTS - The present disclosure provides tissue supports and methods for preparing a cartilage composition for repairing cartilage defects, which is prepared by expanding and integrating small cartilage tissue pieces derived from donor or engineered tissue. The methods and supports described herein promote cell migration and integration of neighboring tissue pieces in culture to form the cartilage composition. Methods of cartilage repair using the cartilage composition are also described. | 2014-06-26 |
20140178344 | ACRYLAMIDE HYDROGELS FOR TISSUE ENGINEERING - Disclosed are acrylamide hydrogels prepared from derivatives of (tetrahydropyranyl)methyl- and (tetrahydrofuranyl)methyl-acrylamide, methods of making the same, and methods of wound healing or tissue generation with acrylamide hydrogels. | 2014-06-26 |
20140178345 | THYMIDINE KINASE - A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered. | 2014-06-26 |
20140178346 | CELLULAR COMPOSITIONS FOR TISSUE ENGINEERING - Cell compositions for tissue engineering are provided which contain a population of autologous, minimally passaged dermal fibroblasts in combination with a tissue engineering matrix or scaffold, or material forming a matrix or scaffold. In one embodiment, the population of fibroblasts is genetically engineered to secrete a therapeutic protein in an amount effective to induce tissue growth or tissue repair when the cell composition is transplanted into a subject in need thereof. For example, the therapeutic protein can be a bone morphogenic protein when the tissue to be treated is bone tissue. A preferred bone morphogenic protein is BMP-2. | 2014-06-26 |
20140178347 | NUTRITIONAL SUPPLEMENT SYSTEM - A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12. | 2014-06-26 |
20140178348 | Methods using DNA methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies - Methods using DNA Methylation arrays are provided for identifying a cell or mixture of cells and for quantification of alterations in distribution of cells in blood or in tissues, and for diagnosing, prognosing and treating disease conditions, particularly cancer. The methods use fresh and archival samples. | 2014-06-26 |
20140178349 | Cycloalkyl-Substituted Imidazole Derivative - A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R | 2014-06-26 |
20140178350 | DEPHOSPHORYLATED LYSOSOMAL STORAGE DISEASE PROTEINS AND METHODS OF USE THEREOF - Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II). | 2014-06-26 |
20140178351 | COMPOSITIONS AND METHODS RELATING TO ARGININOSUCCCINATE SYNTHETASE - Processes and compositions for the therapeutic treatment of pathogenic Gram-negative bacterial infection are provided whereby arginino succinate synthetase or PEGylated arginino succinate synthetase is administered to a subject to inactivate endotoxin thereby reducing the likelihood of bacterial sepsis and improving patient outcome. | 2014-06-26 |
20140178352 | PEPTIDE INHIBITORS OF PROTEIN KINASE C - PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described. | 2014-06-26 |
20140178353 | BACTERIAL ANTI-PHAGE DEFENSE SYSTEMS - An isolated polypeptide is disclosed comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2773-5544 and 11089-11094, wherein the polypeptide has antimicrobial activity. Uses thereof for treating microbial infections are also disclosed. | 2014-06-26 |
20140178354 | Salinosporamides and Methods of Use Thereof - The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet | 2014-06-26 |
20140178355 | Compositions and Methods for Treating Celiac Sprue Disease - The invention provides compositions and methods for treating celiac sprue. | 2014-06-26 |
20140178356 | Stabilised Solid Compositions of Factor VII Polypeptides - The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature. | 2014-06-26 |
20140178357 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS - The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions. | 2014-06-26 |
20140178358 | Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker - The present invention concerns means and methods for predicting the risk of a subject to suffer from liver damage. In particular, it pertains to a method for predicting the risk of a subject to suffer from liver damage caused by acetaminophen comprising determining the amount of putrescine in a blood, serum or plasma sample that has been obtained from the subject after administration of acetaminophen, and comparing the determined amount to a reference, whereby the risk of the subject to suffer from liver damage caused by acetaminophen is predicted. Also provided are devices for carrying out the aforementioned methods. | 2014-06-26 |
20140178359 | Chlorine Dioxide Based Cleanser/Sanitizer - This invention relates to an improved chlorine dioxide solution or liquid mixture containing a phosphate and, as well, as to a composition for forming the chlorine dioxide and phosphate liquid mixture. This improved chlorine dioxide solution is used to clean and/or sanitize without causing corrosion. The corrosion nature of the chlorine dioxide solution is lessened due to the addition of phosphate to the composition. | 2014-06-26 |
20140178360 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS - The present invention relates to pyrimidine compounds of formula (I): | 2014-06-26 |
20140178361 | METHOD FOR POLYCLONAL IMMUNOGLOBULIN G PRODUCTION BY HUMAN B CELLS - This application relates to an in vitro method of producing a polyclonal IgG preparation. The method comprises (i) placing a polyclonal B-cell population enriched in IgG-secreting B cells in a culture medium; and (ii) culturing the polyclonal B-cell population under conditions enabling the production of the polyclonal IgG preparation from the polyclonal B-cell population. This improved method enables the production of antibodies (preferably IgG) and facilitates long-term culture of polyclonal B-cell populations. | 2014-06-26 |
20140178362 | METHODS AND COMPOSITIONS FOR TREATING DISEASES TARGETING MABA - Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of Maba in disease cells compared to healthy cells. Also provided are antagonists or agonists of Maba, and methods for screening agents that modulate the Maba level or activity in vivo or in vitro. | 2014-06-26 |
20140178363 | VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS - Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy. | 2014-06-26 |
20140178364 | COMPOSITIONS AND METHODS FOR TARGETING TYPE 1 INTERFERON PRODUCING CELLS - The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds. | 2014-06-26 |
20140178365 | GLYCAN-INTERACTING COMPOUNDS - The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them. | 2014-06-26 |
20140178366 | PRESELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT BASED ON HYPOXIC STATUS - The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention. | 2014-06-26 |
20140178367 | Methods of Treating Inflammatory Diseases by Targeting the Chemoattractant Cytokine Receptor 2 (CCR2) or Chemokine (C-C motif) Ligand 2 (CCL2) - Methods of treating inflammatory diseases, e.g., diseases associated with inflammatory CD14+/CD16− monocytes, e.g., amyotrophic lateral sclerosis (ALS), stroke, and glaucoma, using compounds such as small molecules and antibodies that target CCR2 or CCL2. | 2014-06-26 |
20140178368 | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INDUCING ANTIBODIES FOR THE TREATMENT OF CANCER - Methods for treating cancer in a patient in need thereof, with a therapeutically effective amount of an anti-4-1BB antibody in combination with a therapeutically effective amount of an ADCC-inducing antibody, are disclosed. | 2014-06-26 |
20140178369 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2014-06-26 |
20140178370 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PERSISTENT INFECTIONS AND CANCER BY INHIBITING THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY - The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer. | 2014-06-26 |
20140178371 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer. | 2014-06-26 |
20140178372 | METHODS OF TREATING HEMATOLOGIC CANCERS - The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits. | 2014-06-26 |
20140178373 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PROPHYLAXIS OF CANCER - An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and/or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and/or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11. | 2014-06-26 |
20140178374 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO - The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof. | 2014-06-26 |
20140178375 | ANTIBODY-LIKE PROTEINS FOR THERAPEUTIC AND DIAGNOSTIC USE - Disclosed herein are recombinant protein scaffolds for use in producing antigen-binding proteins. Related antigen-binding proteins are also provided herein. In addition, nucleic acids encoding such recombinant protein scaffolds and antigen-binding proteins are also described. Vectors and cells useful for expression of the described proteins are also provided, as are methods of use. | 2014-06-26 |
20140178376 | METHOD OF INHIBITING OSTEOCLAST ACTIVITY - Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer. | 2014-06-26 |
20140178377 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYOTONIC DYSTROPHY - In certain embodiments, the present invention provides compositions and methods for treating myotonic dystrophy. | 2014-06-26 |
20140178378 | SGP130/FC DIMERS - Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala | 2014-06-26 |
20140178379 | Therapeutic Nuclease Compositions and Methods - Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal. | 2014-06-26 |
20140178380 | Bi-Specific Fusion Proteins - Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network. | 2014-06-26 |
20140178381 | RETROGRADE TRANSPORT PEPTIDE AND USE OF SAME FOR DELIVERY TO CENTRAL NERVOUS SYSTEM - Transport peptides, alone or attached to a cargo moiety, are capable of targeted axonal import into the spinal cord and other structures of the central nervous system. The transport peptides can be used to deliver therapeutic agents and other molecules of interest from the periphery to the central nervous system, providing a means to detect, treat or prevent neurodegenerative diseases, stroke, chronic pain and other conditions via minimally invasive techniques of administration. | 2014-06-26 |
20140178382 | ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS - The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same. | 2014-06-26 |
20140178383 | STABLE FORMULATIONS OF POLYPEPTIDES AND USES THEREOF - Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from Tween 80, Tween 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower. | 2014-06-26 |
20140178384 | POST-TRANSLATIONALLY MODIFIED NEUROTROPHINS - The present invention describes that neurotrophins undergo post-translational modifications, and that these post-translational modifications mediate the pro-apoptotic and/or pro-neurite activity of neurotrophins. These post-translational modifications notably include nitration and the formation of conformationally-different dimers, as well as of abnormal oligomers, such as tetramers and octamers. The invention further relates to compounds that compete with such modified neurotrophins, as well as to compounds that binds to said modified neurotrophins. The invention thus provides useful agents for the treatment of the conditions or diseases involving chronic pain and/or neuron loss. | 2014-06-26 |
20140178385 | Generation of Anti-FN14 Monoclonal Antibodies by Ex-Vivo Accelerated Antibody Evolution - The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14. | 2014-06-26 |
20140178386 | FUNCTIONALIZED POLYPEPTIDES - The invention provides functionalized polypeptides, especially therapeutic polypeptides (e.g., scFv), comprising a linker sequence that can be rapidly and specifically functionalized by the addition of one or functional moieties (e.g., PEG) or binding specificities (e.g., an amino acid sequence with a particular binding specificity). Such functionalized polypeptides are advantageous in that they have improved pharmacokinetic properties (e.g., improved in vivo half-life, tissue penetration and tissue residency time) over non-functionalized polypeptides. Methods for the rapid and reproducible generation of functionalized polypeptides are also provided. | 2014-06-26 |
20140178387 | ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13 - The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2014-06-26 |
20140178388 | MULTIVALENT ANTIBODY FRAGMENTS AND TRIMERIZED COMPLEXES THEREOF - The present invention relates to a method for producing multivalent Fab fragments. In particular, the invention relates to a method for the generation of trimeric Fab fragments by co-expression of a gene construct comprising a heavy chain portion of a Fab fragment and an in-frame fused collagen-like peptide, and a gene construct consisting of a light chain portion of an IgG in mammalian cells. Uses of molecules generated using the method of the invention are also described. | 2014-06-26 |
20140178389 | IL-1 BINDING PROTEINS - The disclosure provides binding proteins that specifically bind to IL-1α and IL-1β. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1α and/or IL-1β and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation. | 2014-06-26 |
20140178390 | BIOLOGICAL MATERIALS RELATED TO CXCR7 - The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth. | 2014-06-26 |
20140178391 | COLON DISEASE TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon. | 2014-06-26 |
20140178392 | Nogo Receptor-Mediated Blockade of Axonal Growth - Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease. | 2014-06-26 |
20140178393 | AMINO ACID SEQUENCE PRESENTING FUSION POLYPEPTIDE AND ITS USE - Herein is reported a fusion polypeptide according to formula (I): NH | 2014-06-26 |
20140178394 | NOVEL ANTIGEN PEPTIDE AND USES THEREOF - The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer. | 2014-06-26 |
20140178395 | TREATMENT OF NEPHROPATHY - The present invention relates to treatment of nephropathy. In particular, the present invention relates to treatment of nephropathy using therapeutic antibodies. | 2014-06-26 |
20140178396 | TREATMENT OF CARDIOVASCULAR DISEASES - The present invention relates to treatment of cardiovascular diseases and arthero-sclerosis. In particular, the present invention relates to use of therapeutic antibodies. | 2014-06-26 |
20140178397 | ANTI-ANGIOGENIC THERAPY - The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis. | 2014-06-26 |
20140178398 | VASCULAR DISRUPTION AGENTS AND USES THEREOF - Uses of Apo2L/TRAIL polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided. | 2014-06-26 |
20140178399 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS - Certain embodiments are directed to compositions and methods of inhibiting pathogenic bacterial infection involving ADAMIO comprising administering an effective amount of a metalloprotease inhibitor to a patient. Certain embodiments are directed to method of inhibiting Staphylococcal infection comprising administering an effective amount of a metalloprotease inhibitor to a patient. Other embodiments concern methods of inhibiting infection by a bacteria from the genus | 2014-06-26 |
20140178400 | T-Helper Cell Type 17 Lineage-Specific Adjuvants, Compositions and Methods - The present invention relates to compositions and methods for modulation of T | 2014-06-26 |
20140178401 | ANTI-IL-23 ANTIBODIES - The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same. | 2014-06-26 |